Stock comparison
Geron
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GERN
Geron
Market cap
$821.15M
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GERN | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 36D | 70B | HAE |
| Benjamin Graham | 63D | 85A | HAE |
| Philip Fisher | 52C | 60C | HAE |
| Peter Lynch | 20F | 54C | HAE |
| Joel Greenblatt | 2F | 31F | HAE |
| Charlie Munger | 43D | 54D | HAE |
| Terry Smith | 48D | 55D | HAE |
Side-by-side metrics
| Metric | GERN | HAE |
|---|---|---|
| Market cap | $821.15M | $2.98B |
| P/E (TTM) | - | 24.8x |
| EV/EBIT | - | 14.1x |
| ROIC (TTM) | -7.77% | 8.37% |
| Gross margin | 86.59% | 55.74% |
| Net margin | -35.48% | 7.29% |
| Revenue CAGR 5y | 2.39% | 7.65% |
| EPS CAGR 5y | - | 24.62% |
| Debt / Equity | 1.1x | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GERN leads on
- EV/EBIT-vs 14.1x+178%
- P/E (TTM)-vs 24.8x+148%
- Revenue CAGR 5y2.39%vs 7.65%+97%
- Gross margin86.59%vs 55.74%+36%
HAE leads on
- ROIC (TTM)8.37%vs -7.77%+193%
- Net margin7.29%vs -35.48%+121%
- Market cap$2.98Bvs $821.15M+72%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.